{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T23:22:21Z","timestamp":1772320941850,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00213-021-05760-8","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T08:03:26Z","timestamp":1610697806000},"page":"1133-1140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of clonidine on progressive ratio schedule performance in Fmr1 knockout mice"],"prefix":"10.1007","volume":"238","author":[{"given":"Craige C.","family":"Wrenn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"French","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"McCallian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark P.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Valdovinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"5760_CR1","first-page":"2","volume":"12","author":"D Bates","year":"2015","unstructured":"Bates D, Maechler M, Bolker B, Walker S, Christensen RHB, Singman H, Bolker MB (2015) Package 'lme4'. Convergence 12:2","journal-title":"Convergence"},{"key":"5760_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/mrdd.20009","volume":"10","author":"A Beckel-Mitchener","year":"2004","unstructured":"Beckel-Mitchener A, Greenough WT (2004) Correlates across the structural, functional, and molecular phenotypes of fragile X syndrome. Ment Retard Dev Disabil Res Rev 10:53\u201359","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"5760_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00213-012-2771-4","volume":"222","author":"C Bradshaw","year":"2012","unstructured":"Bradshaw C, Killeen P (2012) A theory of behaviour on progressive ratio schedules, with applications in behavioural pharmacology. Psychopharmacology 222:549\u2013564","journal-title":"Psychopharmacology"},{"key":"5760_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00008480-200312000-00003","volume":"15","author":"P Chiurazzi","year":"2003","unstructured":"Chiurazzi P, Neri G, Oostra BA (2003) Understanding the biological underpinnings of fragile X syndrome. Curr Opin Pediatr 15:559\u2013566","journal-title":"Curr Opin Pediatr"},{"key":"5760_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10803-004-1038-2","volume":"35","author":"D Cohen","year":"2005","unstructured":"Cohen D, Pichard N, Tordjman S, Baumann C, Burglen L, Excoffier E, Lazar G, Mazet P, Pinquier C, Verloes A, H\u00e9ron D (2005) Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord 35:103\u2013116. https:\/\/doi.org\/10.1007\/s10803-004-1038-2","journal-title":"J Autism Dev Disord"},{"key":"5760_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5:727\u2013738. https:\/\/doi.org\/10.1016\/S2215-0366(18)30269-4","journal-title":"Lancet Psychiatry"},{"key":"5760_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/yco.0b013e3282ab9952","volume":"20","author":"S Deb","year":"2007","unstructured":"Deb S, Unwin GL (2007) Psychotropic medication for behaviour problems in people with intellectual disability: a review of the current literature. Curr Opin Psychiatry 20:461\u2013466. https:\/\/doi.org\/10.1097\/yco.0b013e3282ab9952","journal-title":"Curr Opin Psychiatry"},{"key":"5760_CR8","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1007\/s10803-019-04173-z","volume":"49","author":"EM Eckert","year":"2019","unstructured":"Eckert EM, Dominick KC, Pedapati EV, Wink LK, Shaffer RC, Andrews H, Choo TH, Chen C, Kaufmann WE, Tartaglia N, Berry-Kravis EM, Erickson CA (2019) Pharmacologic interventions for irritability, aggression, agitation and self-injurious behavior in fragile X syndrome: an initial cross-sectional analysis. J Autism Dev Disord 49:4595\u20134602. https:\/\/doi.org\/10.1007\/s10803-019-04173-z","journal-title":"J Autism Dev Disord"},{"key":"5760_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-med-081117-041238","volume":"70","author":"I Gantois","year":"2019","unstructured":"Gantois I, Popic J, Khoutorsky A, Sonenberg N (2019) Metformin for treatment of fragile X syndrome and other neurological disorders. Annu Rev Med 70:167\u2013181. https:\/\/doi.org\/10.1146\/annurev-med-081117-041238","journal-title":"Annu Rev Med"},{"key":"5760_CR10","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511790942","volume-title":"Data analysis using regression and multilevel\/hierarchical models","author":"A Gelman","year":"2006","unstructured":"Gelman A, Hill J (2006) Data analysis using regression and multilevel\/hierarchical models. Cambridge University Press, Cambridge"},{"key":"5760_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.56021\/9780801868436","volume-title":"Fragile X syndrome: diagnosis, treatment, and research. 3rd Edition edn","author":"RJ Hagerman","year":"2002","unstructured":"Hagerman RJ (2002) The physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ (eds) Fragile X syndrome: diagnosis, treatment, and research. 3rd Edition edn. The Johns Hopkins University Press, Baltimore, pp 3\u2013109"},{"key":"5760_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1037\/a0035988","volume":"128","author":"SM Hamilton","year":"2014","unstructured":"Hamilton SM et al (2014) Fmr1 and Nlgn3 knockout rats: Novel tools for investigating autism spectrum disorders. Behav Neurosci 128:103\u2013109. https:\/\/doi.org\/10.1037\/a0035988","journal-title":"Behav Neurosci"},{"key":"5760_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/0091-3057(92)90001-v","volume":"42","author":"GE Hunt","year":"1992","unstructured":"Hunt GE, Atrens DM (1992) Reward summation and the effects of pimozide, clonidine, and amphetamine on fixed-interval responding for brain stimulation. Pharmacol Biochem Behav 42:563\u2013577. https:\/\/doi.org\/10.1016\/0091-3057(92)90001-v","journal-title":"Pharmacol Biochem Behav"},{"key":"5760_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/cercor\/10.10.1038","volume":"10","author":"SA Irwin","year":"2000","unstructured":"Irwin SA, Galvez R, Greenough WT (2000) Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10:1038\u20131044","journal-title":"Cereb Cortex"},{"key":"5760_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11940-019-0551-8","volume":"21","author":"I Jalnapurkar","year":"2019","unstructured":"Jalnapurkar I, Cochran DM, Frazier JA (2019) New therapeutic options for fragile X syndrome. Curr Treat Options Neurol 21:12. https:\/\/doi.org\/10.1007\/s11940-019-0551-8","journal-title":"Curr Treat Options Neurol"},{"key":"5760_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/acps.12644","volume":"135","author":"K Jobski","year":"2017","unstructured":"Jobski K, H\u00f6fer J, Hoffmann F, Bachmann C (2017) Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. Acta Psychiatr Scand 135:8\u201328. https:\/\/doi.org\/10.1111\/acps.12644","journal-title":"Acta Psychiatr Scand"},{"key":"5760_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/bf00427419","volume":"83","author":"JL Katz","year":"1984","unstructured":"Katz JL (1984) Effects of clonidine and some alpha-adrenergic antagonists alone and in combination on schedule-controlled behavior in pigeons and mice. Psychopharmacology 83:38\u201343. https:\/\/doi.org\/10.1007\/bf00427419","journal-title":"Psychopharmacology"},{"key":"5760_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/BF00441939","volume":"98","author":"JL Katz","year":"1989","unstructured":"Katz JL (1989) Interactions of clonidine and naloxone on schedule-controlled behavior in opioid-naive mice. Psychopharmacology 98:445\u2013447","journal-title":"Psychopharmacology"},{"key":"5760_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1017\/S0140525X00033628","volume":"17","author":"PR Killeen","year":"1994","unstructured":"Killeen PR (1994) Mathematical principles of reinforcement. Behav Brain Sci 17:105\u2013135. https:\/\/doi.org\/10.1017\/S0140525X00033628","journal-title":"Behav Brain Sci"},{"key":"5760_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13041-017-0312-0","volume":"10","author":"EW Kim","year":"2017","unstructured":"Kim EW, Phillips BU, Heath CJ, Cho SY, Kim H, Sreedharan J, Song HT, Lee JE, Bussey TJ, Kim CH, Kim E, Saksida LM (2017) Optimizing reproducibility of operant testing through reinforcer standardization: identification of key nutritional constituents determining reward strength in touchscreens. Mol Brain 10:31. https:\/\/doi.org\/10.1186\/s13041-017-0312-0","journal-title":"Mol Brain"},{"key":"5760_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.braindev.2010.05.011","volume":"33","author":"A Lo-Castro","year":"2011","unstructured":"Lo-Castro A, D'Agati E, Curatolo P (2011) ADHD and genetic syndromes. Brain and Development 33:456\u2013461","journal-title":"Brain and Development"},{"key":"5760_CR22","doi-asserted-by":"publisher","first-page":"e4f972cffe982c9","DOI":"10.1371\/4f972cffe82c0","volume":"4","author":"S Oakeshott","year":"2012","unstructured":"Oakeshott S et al (2012) A mixed fixed ratio\/progressive ratio procedure reveals an apathy phenotype in the BAC HD and the z_Q175 KI mouse models of Huntington's disease. PLoS Curr 4:e4f972cffe982c970. https:\/\/doi.org\/10.1371\/4f972cffe82c0","journal-title":"PLoS Curr"},{"key":"5760_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(91)90125-i","volume":"66","author":"M Pieretti","year":"1991","unstructured":"Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL (1991) Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66:817\u2013822. https:\/\/doi.org\/10.1016\/0092-8674(91)90125-i","journal-title":"Cell"},{"key":"5760_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0376-6357(03)00027-5","volume":"62","author":"MP Reilly","year":"2003","unstructured":"Reilly MP (2003) Extending mathematical principles of reinforcement into the domain of behavioral pharmacology. Behav Process 62:75\u201388. https:\/\/doi.org\/10.1016\/S0376-6357(03)00027-5","journal-title":"Behav Process"},{"key":"5760_CR25","doi-asserted-by":"publisher","unstructured":"Sharma S, Hryhorczuk C, Fulton S (2012) Progressive-ratio responding for palatable high-fat and high-sugar food in mice. J Vis Exp:e3754. https:\/\/doi.org\/10.3791\/3754","DOI":"10.3791\/3754"},{"key":"5760_CR26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/0091-3057(90)90112-u","volume":"36","author":"JB Smith","year":"1990","unstructured":"Smith JB (1990) Effects of fixed-ratio requirement on observed tolerance to decreased responding by clonidine. Pharmacol Biochem Behav 36:993\u2013995. https:\/\/doi.org\/10.1016\/0091-3057(90)90112-u","journal-title":"Pharmacol Biochem Behav"},{"key":"5760_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2165\/00023210-200418110-00001","volume":"18","author":"JA Tsiouris","year":"2004","unstructured":"Tsiouris JA, Brown WT (2004) Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy. CNS Drugs 18:687\u2013703","journal-title":"CNS Drugs"},{"key":"5760_CR28","doi-asserted-by":"publisher","first-page":"g4323","DOI":"10.1136\/bmj.g4323","volume":"349","author":"P Tyrer","year":"2014","unstructured":"Tyrer P, Cooper S-A, Hassiotis A (2014) Drug treatments in people with intellectual disability and challenging behaviour. BMJ 349:g4323. https:\/\/doi.org\/10.1136\/bmj.g4323","journal-title":"BMJ"},{"key":"5760_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40474-019-00179-5","volume":"6","author":"MG Valdovinos","year":"2019","unstructured":"Valdovinos MG (2019) Psychotropic medication in intellectual and developmental disabilities: patterns of use and recommendations for monitoring effects. Curr Dev Disord Rep 6:195\u2013201. https:\/\/doi.org\/10.1007\/s40474-019-00179-5","journal-title":"Curr Dev Disord Rep"},{"key":"5760_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10882-008-9123-7","volume":"21","author":"MG Valdovinos","year":"2009","unstructured":"Valdovinos MG, Parsa RA, Alexander ML (2009) Results of a nation-wide survey evaluating psychotropic medication use in fragile X syndrome. J Dev Phys Disabil 21:23\u201337","journal-title":"J Dev Phys Disabil"},{"key":"5760_CR31","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3758\/bf03206482","volume":"11","author":"EJ Wagenmakers","year":"2004","unstructured":"Wagenmakers EJ, Farrell S (2004) AIC model selection using Akaike weights. Psychon Bull Rev 11:192\u2013196. https:\/\/doi.org\/10.3758\/bf03206482","journal-title":"Psychon Bull Rev"},{"key":"5760_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neulet.2014.11.035","volume":"585","author":"CC Wrenn","year":"2015","unstructured":"Wrenn CC, Heitzer AM, Roth AK, Nawrocki L, Valdovinos MG (2015) Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice. Neurosci Lett 585:109\u2013113. https:\/\/doi.org\/10.1016\/j.neulet.2014.11.035","journal-title":"Neurosci Lett"},{"key":"5760_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1901\/jeab.1996.65-603","volume":"65","author":"CD Wynne","year":"1996","unstructured":"Wynne CD, Staddon JE, Delius JD (1996) Dynamics of waiting in pigeons. J Exp Anal Behav 65:603\u2013618","journal-title":"J Exp Anal Behav"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05760-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-021-05760-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05760-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T19:59:47Z","timestamp":1697572787000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-021-05760-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5760"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05760-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Principles of laboratory animal care and use were followed, and all procedures were approved by the Drake University Institutional Animal Care and Use Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}